1,267 posters, 47 videos, 13 topics, 4 sessions, 853 authors

SOHO 2026 Annual Meeting

September 9 - 12, 2026 | George R. Brown Convention Center, Houston, Texas

Posters by Title

Showing 1,267 results.

AML - 222

Global Inequities in Leukemia Survival Persist Despite Overall Gains: GBD 2023 MIR Trends, 1990-2023

Tapan Giri

Poster Presenter: Tapan Giri

CLL - 1757

Global Macroeconomic Burden of Leukemia Attributable to Tobacco: A Value-of-Lost-Welfare Analysis Across 184 Countries

Kashish Magnani

Poster Presenter: Kashish Magnani

Thumbnail for Global Research Landscape and Emerging Hotspots in CAR-NK Cell Therapy for Hematologic Malignancies: A Bibliometric Analysis (2015-2026)

CT - 1397

Global Research Landscape and Emerging Hotspots in CAR-NK Cell Therapy for Hematologic Malignancies: A Bibliometric Analysis (2015-2026)

Pranathi Reddy Jetti

Poster Presenter: Pranathi Reddy Jetti

Thumbnail for Global Trends and Emerging Hotspots in Artificial Intelligence Research for Acute Myeloid Leukemia: A Bibliometric Analysis From 2015 to 2026

AML - 1696

Global Trends and Emerging Hotspots in Artificial Intelligence Research for Acute Myeloid Leukemia: A Bibliometric Analysis From 2015 to 2026

Kavita Sehrawat

Poster Presenter: Kavita Sehrawat

Video

Thumbnail for Global, Regional, and National Macroeconomic Burden of Acute Myeloid Leukemia: A Value-of-Lost-Welfare Analysis of 184 Countries, 2023

AML - 1359

Global, Regional, and National Macroeconomic Burden of Acute Myeloid Leukemia: A Value-of-Lost-Welfare Analysis of 184 Countries, 2023

Sai Varun Gadde

Poster Presenter: Sai Varun Gadde

Thumbnail for Global, Regional, and National Macroeconomic Burden of Multiple Myeloma: An Age-Stratified Value-of-Lost-Welfare Analysis of 184 Countries, 2023

MM - 1692

Global, Regional, and National Macroeconomic Burden of Multiple Myeloma: An Age-Stratified Value-of-Lost-Welfare Analysis of 184 Countries, 2023

Hardik Dineshbhai Desai

Poster Presenter: Hardik Dineshbhai Desai

Thumbnail for Global, Regional, and Socio-Demographic Disparities in Hodgkin Lymphoma Burden in the Checkpoint Inhibitor Era (2016-2023): A Global Burden of Disease 2023 Analysis With Implications for Equitable Immunotherapy Access

HL - 199

Global, Regional, and Socio-Demographic Disparities in Hodgkin Lymphoma Burden in the Checkpoint Inhibitor Era (2016-2023): A Global Burden of Disease 2023 Analysis With Implications for Equitable Immunotherapy Access

Tapan Giri

Poster Presenter: Tapan Giri

$Thumbnail for Glofitamab Plus Gemcitabine and Oxaliplatin (GemOx) Versus Rituximab Plus GemOx (R-GemOx) in Patients With Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): Outcomes from the 3-Year Follow-Up of STARGLO$

ABCL - 483

Glofitamab Plus Gemcitabine and Oxaliplatin (GemOx) Versus Rituximab Plus GemOx (R-GemOx) in Patients With Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): Outcomes from the 3-Year Follow-Up of STARGLO

Haifaa Abdulhaq

Poster Presenter: Haifaa Abdulhaq

Thumbnail for GLP-1 Agonists Improve Survival and Reduce Morbidity in Newly Diagnosed Multiple Myeloma: A Real-World Propensity Score-Matched Analysis

MM - 1225

GLP-1 Agonists Improve Survival and Reduce Morbidity in Newly Diagnosed Multiple Myeloma: A Real-World Propensity Score-Matched Analysis

Chidiebube Ugwu

Poster Presenter: Chidiebube Ugwu